Please login to the form below

Not currently logged in
Email:
Password:

Accretio appoints Neil Levinson as strategy director

He joins the healthcare consultancy from Kaiser Associates

AccretioAccretio, part of the OPEN health group of companies, has appointed Neil Levinson as its strategy director.

Levinson will join the Accretio leadership team alongside managing director Richard Baderin and operations director Charlotte Richards.

Speaking of his new appointment, Levinson said: “Accretio has pioneered novel ways to support life science companies achieve improved results for their brand.

“I look forward to expanding this offering and maximising the breadth of experience from the broader OPEN Health group to provide outcomes-focused consulting and implementation services for global and UK clients.”

Most recently, Levinson was vice president at Kaiser Associates, a global strategy-consulting firm, where he led the European healthcare practice.

Prior to Kaiser, Levinson spent ten years at IMS Health, where he was senior principal, leading the UK and Ireland consulting services business.

Commenting on his appointment, Baderin, said: “Neil’s appointment cements Accretio’s evolution to a fully-fledged strategic solutions and implementation services company led by a team with pharmaceutical, consultancy and agency heritage.

“It’s great to have someone of Neil’s calibre as part of the leadership team as we embark on the next phase of Accretio’s journey.”

24th April 2018

From: Marketing

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Research Partnership

We are the largest independent healthcare market research and consulting agencies in the world. Trusted partner to the global pharmaceutical...

Latest intelligence

Peter Howarth
Exploring the potential of eosinophils
GSK’s Peter Howarth talks about the emerging research that suggests there is a varied role for eosinophils...
white house
Eliminating pharmaceutical rebates, is this déjà vu?
By Andrew Parece and Matthew Majewski...
Patients are ready to embrace decentralised clinical trials, are you?
Traditional clinical trial designs simply can’t withstand the impact of COVID-19. While before the pandemic, some in clinical research were beginning to adopt virtual components, the move towards designing hybrid...

Infographics